[ Price : $8.95]
FDA increases scrutiny of telehealth companies marketing compounded drugs, warning that some firms are making false or misleading ...[ Price : $8.95]
Neumora Therapeutics discontinues development of its lead depression candidate navacaprant after two Phase 3 studies failed to mee...[ Price : $8.95]
FDA posts a draft guidance to assist NDA sponsors in properly submitting patent information for listing in the agency's Orange Boo...[ Price : $8.95]
FDA approves Merck's Welireg (belzutifan) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for certain patien...[ Price : $8.95]
A just-posted notice from Amgen outlines the basis for the company's defense of why its ANCA-associated vasculitis drug Tavneos sh...[ Price : $8.95]
Jazz Pharmaceuticals says its Phase 3 LAGOON study evaluating Zepzelca (lurbinectedin) in relapsed small cell lung cancer failed t...[ Price : $8.95]
FDA approves AstraZeneca's AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN...[ Price : $8.95]
Some 17 Senate Democrats write to HHS secretary Robert F. Kennedy Jr., questioning many of his personnel decisions and expressing ...